Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-08-21

FDA Approved: VENLAFAXINE — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved a supplemental application for Venlafaxine from BluePoint Laboratories, confirming a generic venlafaxine product (venlafaxine hydrochloride).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Venlafaxine (Venlafaxine)

Snippet

SUPPL AP for VENLAFAXINE (VENLAFAXINE)